Alan Faraj

A noninvasive BCG skin challenge model for assessing tuberculosis vaccine efficacy

Krishnan, Nitya; Priestman, Miles; Uhia, Iria; Charitakis, Natalie et al.

Ingår i PLoS biology, 2024

• DOI för A noninvasive BCG skin challenge model for assessing tuberculosis vaccine efficacy
• Ladda ner fulltext (pdf) av A noninvasive BCG skin challenge model for assessing tuberculosis vaccine efficacy

Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors

Faraj, Alan; Nyberg, Joakim; Blouse, Grant E.; Knudsen, Tom et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 498-505, 2024

• DOI för Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors
• Ladda ner fulltext (pdf) av Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors

Pharmacometric models to inform dose selection and study design: Applied in hemophilia and tuberculosis

Faraj, Alan

2024

• Ladda ner fulltext (pdf) av Pharmacometric models to inform dose selection and study design: Applied in hemophilia and tuberculosis

Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development

Mockeliunas, Laurynas; Faraj, Alan; Van Wijk, Rob C; Upton, Caryn M. et al.

Ingår i Frontiers in Pharmacology, 2023

• DOI för Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development
• Ladda ner fulltext (pdf) av Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development

Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy

Faraj, Alan; Van Wijk, Rob C; Neuman, Linda; Desai, Shraddha et al.

Ingår i CPT, s. 977-987, 2023

• DOI för Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy
• Ladda ner fulltext (pdf) av Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy

A noninvasive BCG skin challenge model for assessing tuberculosis vaccine efficacy

Krishnan, Nitya; Priestman, Miles; Uhia, Iria; Charitakis, Natalie et al.

Ingår i PLoS biology, 2024

• DOI för A noninvasive BCG skin challenge model for assessing tuberculosis vaccine efficacy
• Ladda ner fulltext (pdf) av A noninvasive BCG skin challenge model for assessing tuberculosis vaccine efficacy

Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors

Faraj, Alan; Nyberg, Joakim; Blouse, Grant E.; Knudsen, Tom et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 498-505, 2024

• DOI för Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors
• Ladda ner fulltext (pdf) av Subcutaneous Marzeptacog Alfa (Activated) for On‐Demand Treatment of Bleeding Events in Subjects With Hemophilia A or B With Inhibitors

Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development

Mockeliunas, Laurynas; Faraj, Alan; Van Wijk, Rob C; Upton, Caryn M. et al.

Ingår i Frontiers in Pharmacology, 2023

• DOI för Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development
• Ladda ner fulltext (pdf) av Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development

Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy

Faraj, Alan; Van Wijk, Rob C; Neuman, Linda; Desai, Shraddha et al.

Ingår i CPT, s. 977-987, 2023

• DOI för Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy
• Ladda ner fulltext (pdf) av Model-informed pediatric dose selection of marzeptacog alfa (activated): An exposure matching strategy

Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients

Faraj, Alan; Le Moan, Natacha; Gorina, Eduard; Blouse, Grant E. E. et al.

Ingår i Advances in Therapy, s. 3739-3750, 2023

• DOI för Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients
• Ladda ner fulltext (pdf) av Model-Informed Support of Dose Selection for Prophylactic Treatment with Dalcinonacog Alfa in Adult and Paediatric Hemophilia B Patients

Cough as Noninvasive Biomarker for Monitoring Tuberculosis Treatment: A Proof-of-Concept Study

Janssen, Saskia; Upton, Caryn M.; De Jager, Veronique R.; Faraj, Alan et al.

Ingår i Annals of the American Thoracic Society, s. 1822-1825, 2023

• DOI för Cough as Noninvasive Biomarker for Monitoring Tuberculosis Treatment: A Proof-of-Concept Study

Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug

Faraj, Alan; Knudsen, Tom; Desai, Shraddha; Neuman, Linda et al.

Ingår i CPT, s. 1628-1637, 2022

• DOI för Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug
• Ladda ner fulltext (pdf) av Phase III dose selection of marzeptacog alfa (activated) informed by population pharmacokinetic modeling: A novel hemostatic drug

Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial

De Jager, Veronique; Gupte, Nikhil; Nunes, Silvia; Barnes, Grace L. et al.

Ingår i American Journal of Respiratory and Critical Care Medicine, s. 1228-1235, 2022

• DOI för Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial

Difference in persistent tuberculosis bacteria between in vitro and sputum from patients: implications for translational predictions

Faraj, Alan; Clewe, Oskar; Svensson, Robin J.; Mukamolova, Galina V. et al.

Ingår i Scientific Reports, 2020

• DOI för Difference in persistent tuberculosis bacteria between in vitro and sputum from patients: implications for translational predictions
• Ladda ner fulltext (pdf) av Difference in persistent tuberculosis bacteria between in vitro and sputum from patients: implications for translational predictions

A model-based analysis identifies differences in phenotypic resistance between in vitro and in vivo: implications for translational medicine within tuberculosis.

Clewe, Oskar; Faraj, Alan; Hu, Yanmin; Coates, Anthony R M et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 421-430, 2020

• DOI för A model-based analysis identifies differences in phenotypic resistance between in vitro and in vivo: implications for translational medicine within tuberculosis.
• Ladda ner fulltext (pdf) av A model-based analysis identifies differences in phenotypic resistance between in vitro and in vivo: implications for translational medicine within tuberculosis.

Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients

Faraj, Alan; Svensson, Robin J.; Diacon, Andreas H.; Simonsson, Ulrika S H

Ingår i Antimicrobial Agents and Chemotherapy, 2020

• DOI för Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients
• Ladda ner fulltext (pdf) av Drug Effect of Clofazimine on Persisters Explains an Unexpected Increase in Bacterial Load in Patients

Pharmacometric models to inform dose selection and study design: Applied in hemophilia and tuberculosis

Faraj, Alan

2024

• Ladda ner fulltext (pdf) av Pharmacometric models to inform dose selection and study design: Applied in hemophilia and tuberculosis

Drug effect of clofazimine on persisters explain an unexpected increase in bacterial load from patients

Faraj, Alan; Svensson, Robin J.; Diacon, Andreas H.; Simonsson, Ulrika S H

Model-based approaches to prospectively power pediatric pharmacokinetic trials with limited sample size

Faraj, Alan; Ayoun Alsoud, Rami; Nyberg, Joakim; Simonsson, Ulrika S. H.